Since this thread is supposed to cover all UK topics, it seems the best place to discuss the plans for sharing of medical records - the General Practice Data for Planning and Research (GPDPR) system.

I find myself a bit torn on this one, though I have in the end decided to opt-out. However, the way drugs are developed and tested is strongly focused on the their effects in isolation: it is simply impractical to consider all the interactions of a specific drug with all the other drugs on the market. You can check the more obvious interactions, but not much more.   To discover these, you ultimately rely on an individual patient who is taking two or more drugs to report symptoms, that the doctor concerned notices a connection and reports that upwards until eventually that is assessed and recorded as an incompatibility. A data set where all the drugs each patient is taken can be assessed and their interactions determined is potentially a life saver, and shows every sign of being a major health benefit.

But all that level of analysis, detecting of subtle relationships and whatnot is almost entirely in the commercial sector with things like Palantir.

I do not like putting that level of trust in the hands of companies who could easily exploit it.   Promises the data will never be abused, like those on the NHS Digital website would be fine, if there were no criminals anywhere in the world and everyone could be relied on to stay within the law.

So it comes down to how we trade benefit and risk.   As I say, I have decided the risk is too great, but I am not certain of my opinion.